Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab and Senaparib in Advanced Solid Tumors
NCT05262842Phase 1Withdrawn
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Mar 2022
- Primary completion
- Apr 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
01
Overview
Phase 1, open-label trial of toripalimab and senaparib in solid tumor (advanced stage), endometrial cancer (EC), breast cancer and 7 more, sponsored by Shanghai Junshi Biosciences Co., Ltd. Planned start Mar 2022; status: withdrawn.
02
Drugs
toripalimabsenaparib
03
Conditions
solid tumor (advanced stage)endometrial cancer (EC)breast cancersmall cell lung cancer (SCLC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05262842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05262842.